Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

IONIS PHARMACEUTICALS INC (IONS)

As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data

Report price $28.01 (close 2026-11-16); latest close $26.58 (2026-11-20), -5.1% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case -31% · downside -52% · upside +28%

At $28.01 the market pays $5.03B of enterprise value, 5.23x trailing revenue of $960.1M, for a business that lost $564.9M at the operating line and burned $616.3M of free cash flow over the same twelve months. The base case is $18.32, -34.6%, on EV/Sales at 3.55x, the peer median EV/Sales; the downside is $12.82, -54.2%, on the base case's multiple on -30.0% earnings (the peers trade below the compressed multiple); the upside is $34.05, +21.5%, on +20% sales at today's EV/Sales of 5.23x. The de-rating is real—4.86x price/sales sits below the five-fiscal-year median of 9.1x—but that history priced a company with no positive operating year from FY2020 to the trailing twelve months. The reverse DCF needs only -1.2% revenue a year for ten years, well below the +33.8% just delivered, yet a 20% FCF margin that does not exist. With the base below the price, the cash-flow bridge unbuilt, and a $1.88B cash pile making the story binary on a Q4 2026 EU decision, WATCH is the call at low conviction; short interest is already 12.9% of the float.

Key numbers

  • Share price: $26.58
  • Market cap: $4.43B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $960.1M
  • FCF yield: -13.9%
  • Price / book: 11.25x
  • Earnings-quality flags (TTM): none flagged
  • Revenue growth (latest fiscal year): +33.8%
  • ROIC (TTM): -43.5%
  • WACC: 5.3%
  • Economic profit spread: -48.8 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    IONIS makes money from seven marketed RNA medicines—two now launched independently in the U.S. and several partnered—plus partner royalties and collaboration economics; FY2025 revenue was $944 million with $2.7 billion of cash, cash equivalents and short-term investments. The FY2020-FY2025 cycle shows revenue recovering to $943.7M in FY2025 and $960.1M TTM to Sep 2026, but operating losses and operating cash burn widened, with TTM operating income -$564.9M and TTM operating cash flow -$544.4M. Net income is negative in every supplied period, so normalized valuation should rest on operating and cash-flow trends, not net income.

  2. ✓ 2. Competitive advantage

    The numbers show no durable advantage: revenue went from $729.3M (FY2020) to $943.7M (FY2025) and $960.1M (TTM to 2026-09-30), yet operating income was negative in every one of those periods and reached -$564.9M on the TTM basis, with operating cash flow of -$544.4M TTM. The company's own competition disclosure names approved or late-stage rivals for every marketed medicine — including oral products in HAE and ATTR — and its risk factors state that competitors have substantially greater financial, technical and human resources while IONIS has limited independent commercialization and commercial-scale oligonucleotide manufacturing experience. No source claims brand, cost, network, switching-cost or scale advantage; the only stated differentiation is the chemistry, delivery and behaviour of the medicines versus traditional small molecules, and that claim carries no supporting financial metric.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 total revenue was $243M versus $157M in Q3 2025, but the mix shifted to $48M of product sales (DAWNZERA $37M, TRYNGOLZA $9M, ZANVASTRO $2M) plus $107M of R&D revenue, and the quarter still lost $(130)M from operations on a GAAP basis, $(87)M non-GAAP. Nine-month 2026 revenue of $757M barely exceeded the $740M of the nine months to Sep 2025 because that prior period contained the $280M sapablursen upfront payment, and the nine-month operating loss widened to $(350)M from $(167)M as operating expenses rose to $1,107M from $907M. FY2026 guidance is reaffirmed at $875-900M total revenue, a $425-475M non-GAAP operating loss and cash above $1.6B, with TRYNGOLZA product sales guidance cut to about $50M from $100-110M and DAWNZERA held at $110-120M. Cash fell to $1.9B at Sep 30, 2026 from $2.7B at Dec 31, 2025 after the April 1, 2026 convertible repayment.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans